GeroScience,
Journal Year:
2023,
Volume and Issue:
unknown
Published: May 25, 2023
Abstract
Thirteen
percent
of
the
Danish
population
are
treated
with
a
statin—half
these
in
primary
prevention,
and
most
>
65
years
old.
Statins
have
known
muscular
side
effects
(i.e.,
myalgia)
correlated
to
reduced
muscle
performance.
This
study
examines
if
statin
treatment
older
people
introduce
subclinical
discomfort
loss
mass
strength.
In
total,
98
participants
(71.1
±
3.6
(mean
SD)),
who
were
prevention
for
elevated
plasma
cholesterol
statin,
included
this
study.
Statin
was
discontinued
2
months
then
re-introduced
months.
Primary
outcomes
performance
myalgia.
Secondary
lean
cholesterol.
Functional
capacity
measured
as
6-min
walk
test
increased
after
discontinuation
(from
542
88
555
91
m,
P
<
0.05)
remained
re-introduction
(557
94
m).
Similar
significant
results
found
chair
stand
(15.7
4.3
16.3
4.9
repetitions/30
s)
quadriceps
test.
Muscle
during
rest
did
not
change
significantly
(visual
analog
scale
from
0.9
1.7
0.6
1.4)
but
(
(to
1.2
2.0)
activity
decreased
2.5
2.6
1.9
2.3).
After
weeks
discontinuation,
low-density
lipoprotein
2.2
0.5
3.9
0.8
mM
until
statins
0.05).
Significant
lasting
improvements
myalgia
at
statins.
The
indicate
possible
statin-related
persons
that
needs
further
examination.
Journal of the American Geriatrics Society,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 10, 2025
ABSTRACT
The
risk
of
atherosclerotic
cardiovascular
disease
increases
with
advancing
age.
Elevated
LDL‐cholesterol
and
non‐HDL‐cholesterol
levels
remain
predictive
incident
events
among
individuals
older
than
75
years.
Risk
prediction
is
less
certain
because
most
current
calculators
lack
specificity
in
those
years
do
not
adjust
for
co‐morbidities,
functional
status,
frailty,
cognition
which
significantly
impact
prognosis
this
age
group.
Data
on
the
benefits
risks
lowering
statins
patients
without
are
also
limited
since
primary
prevention
trials
have
included
mostly
younger
patients.
Available
data
suggest
that
statin
therapy
may
reduce
from
lipid‐lowering
outweigh
potential
such
as
statin‐associated
muscle
symptoms
Type
2
diabetes
mellitus.
While
some
evidence
suggests
possibility
be
associated
cognitive
impairment
adults,
a
preponderance
literature
indicates
neutral
or
even
protective
statin‐related
effects.
Shared
decision‐making
recommended
all
when
considering
particularly
important
Randomized
clinical
trial
evaluating
use
non‐statin
sparse.
Deprescribing
agents
appropriate
select
life‐limiting
diseases.
Finally,
patient‐centered
approach
should
taken
strategies
adults.
Journal of the American Geriatrics Society,
Journal Year:
2023,
Volume and Issue:
72(2), P. 410 - 422
Published: Dec. 7, 2023
Abstract
Background
Statins
are
part
of
long‐term
medical
regimens
for
many
older
adults.
Whether
frailty
modifies
the
protective
relationship
between
statins,
mortality,
and
major
adverse
cardiovascular
events
(MACE)
is
unknown.
Methods
This
was
a
retrospective
study
US
Veterans
≥65,
without
CVD
or
prior
statin
use
seen
in
2002–2012,
followed
through
2017.
A
31‐item
index
used.
The
co‐primary
endpoint
all‐cause
mortality
MACE
(MI,
stroke/TIA,
revascularization,
death).
Cox
proportional
hazards
models
were
developed
to
evaluate
association
with
outcomes;
propensity
score
overlap
weighting
accounted
confounding
by
indication.
Results
We
identified
710,313
(mean
age
(SD)
75.3(6.5),
98%
male,
89%
white);
86,327
(12.1%)
frail.
Over
mean
follow‐up
8
(5)
years,
there
48.6
72.6
deaths
per
1000
person‐years
(PY)
among
non‐frail
statin‐users
vs
nonusers
(weighted
Incidence
Rate
Difference
(wIRD)/1000
person
years
(PY),
−24.0[95%
CI,
−24.5
−23.6]),
90.4
130.4
1000PY
frail
(wIRD/1000PY,
−40.0[95%
−41.8
−38.2]).
There
51.7
60.8
−9.1[95%
−9.7
−8.5]),
88.2
102.0
−13.8[95%
−16.2
−11.4]).
no
significant
interactions
users
non‐users
either
outcomes,
p‐interaction
0.770
0.319,
respectively.
Statin
associated
lower
risk
(HR,
0.61
(0.60–0.61))
(HR
0.86
(0.85–0.87)).
Conclusions
New
MACE,
independent
frailty.
These
findings
should
be
confirmed
randomized
clinical
trial.
Biology,
Journal Year:
2023,
Volume and Issue:
12(8), P. 1154 - 1154
Published: Aug. 21, 2023
Cognitive
impairment
(CI)
shares
common
cardiovascular
risk
factors
with
acute
myocardial
infarction
(AMI),
and
is
increasingly
prevalent
in
our
ageing
population.
Whilst
AMI
associated
increased
rates
of
CI,
CI
remains
underreported
infrequently
identified
patients
AMI.
In
this
review,
we
discuss
the
evidence
surrounding
its
links
to
dementia
including
pathophysiology,
factors,
management
interventions.
Vascular
dysregulation
plays
a
major
role
atherosclerosis,
platelet
activation,
microinfarcts
perivascular
inflammation
resulting
neurovascular
unit
dysfunction,
disordered
homeostasis
dysfunctional
neurohormonal
response.
This
subsequently
affects
perfusion
pressure,
enlarged
periventricular
spaces
hippocampal
sclerosis.
The
activation
seen
coronary
artery
disease
(CAD)
can
also
result
amyloid-β
protein
deposition
which
Alzheimer’s
Dementia.
Post-AMI,
reduced
blood
pressure
left
ventricular
ejection
fraction
cause
chronic
cerebral
hypoperfusion,
failure
normal
circulatory
autoregulatory
mechanisms.
Patients
who
undergo
revascularization
(percutaneous
intervention
or
bypass
surgery)
are
at
for
post-procedure
cognitive
impairment,
though
whether
related
itself
underlying
debated.
Mortality
higher
AMI,
post-AMI
more
elderly
heart
failure.
Medical
(antiplatelet,
statin,
renin-angiotensin
system
inhibitors,
cardiac
rehabilitation)
reduce
CI;
however,
beta-blockers
may
be
functional
decline
existing
CI.
early
identification
those
present
important,
as
subsequent
tailoring
strategies
potentially
improve
outcomes
well
guide
prognosis.
JACC Advances,
Journal Year:
2024,
Volume and Issue:
3(2), P. 100820 - 100820
Published: Jan. 11, 2024
The
1986
Bethesda
Conference
on
Cardiovascular
Disease
(CVD)
in
the
Elderly,
co-chaired
by
Drs
Nanette
Wenger,
Frank
Marcus,
and
Robert
O'Rourke
delineated
anticipated
social,
political,
ethical,
economic,
technological
impact
of
an
aging
population
incidence,
prevalence,
management
CVD
United
States
worldwide.
In
ensuing
4
decades,
older
patients
have
come
to
comprise
increasingly
large
proportion
population,
there
has
been
explosion
research
all
aspects
affecting
adults.
Correspondingly,
geriatric
cardiology
is
now
established
field
within
cardiovascular
medicine.
this
communication,
we
provide
a
focused
update
intersections
between
geriatrics
from
basic
science
clinical
practice,
review
major
advances
diagnosis
treatment
adults
with
CVD,
preview
future
directions
still-evolving
cardiology.
Circulation Cardiovascular Quality and Outcomes,
Journal Year:
2024,
Volume and Issue:
17(8)
Published: Aug. 1, 2024
Cardiovascular
disease
exacts
a
heavy
toll
on
health
and
quality
of
life
is
the
leading
cause
death
among
people
≥65
years
age.
Although
medical,
surgical,
device
therapies
can
certainly
prolong
span,
progression
from
chronic
to
advanced
end
stage
temporally
unpredictable,
uncertain,
marked
by
worsening
symptoms
that
result
in
recurrent
hospitalizations
excessive
care
use.
Compared
with
other
serious
illnesses,
medication
management
incorporates
palliative
approach
underused
individuals
cardiovascular
disease.
This
scientific
statement
describes
pharmacotherapy
inclusive
drugs
essential
medicines
work
synergistically
control
enhance
life.
We
also
summarize
clarify
available
evidence
utility
guideline-directed
evidence-based
medical
end-stage
heart
failure,
pulmonary
arterial
hypertension,
coronary
disease,
cardiomyopathies
while
providing
clinical
considerations
for
de-escalating
or
deprescribing.
Shared
decision-making
goal-oriented
are
emphasized
considered
quintessential
iterative
process
patient-centered
across
spectrum
